The study is being conducted to compare JS004 plus Toripalimab with Investigator-Selected Chemotherapy in Patients with PD-(L)1 monoclonal antibody refractory Classic Hodgkin Lymphoma (cHL)
Age at least 18 years old, both males and females are eligible
Pathologically confirmed classical Hodgkin Lymphoma (cHL) with either relapsed (disease progression after achieving CR/PR in recent treatment) or refractory (failure to achieve CR/PR in recent treatment) status.
Has exhausted all standard treatment and refractory to PD-(L)1 monoclonal antibody (mAb)
ECOG: 0-2
Known allergy or contraindication to the investigational drug or its components
Permanent discontinuation of anti-PD-(L)1 antibody due to immune-related adverse reactions.
Presence of central nervous system (CNS) metastasis.
Presence of pleural effusion, ascites, or pericardial effusion requiring intervention (e.g., aspiration, drainage)